Clinical Trial

KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V mutation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-05; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-28
Trial Details
NCT Number NCT06767046
Lead Sponsor Corregene Biotechnology Co., Ltd
Conditions Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)
Enrollment 8 participants
Start Date 2025-02-18
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-25